Compare BridgeBio Pharma Inc (BBIO) vs Fortinet Inc (FTNT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs Fortinet Inc — how do they compare? BridgeBio Pharma Inc trades at $84.09 (market cap $16.27B), while Fortinet Inc trades at $167.05 (market cap $117.68B). The key difference: Fortinet Inc is far larger — about 7.2× BridgeBio Pharma Inc's market cap, and Fortinet Inc is trading nearer its 52-week high, BridgeBio Pharma Inc nearer its low. Which is the better fit depends on your goals.
| BBIO | FTNT | |
|---|---|---|
Market Cap | $16.27B | $117.68B |
Sector | Health | Technology |
52-Week High | $90.17 | $166.83 |
52-Week Low | $44.81 | $74.39 |
Enterprise Value | $17.82B | $114.88B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BridgeBio Pharma (BBIO) trades at $83.08, down 3.27% today, near its 52-week high. The stock shows bullish technical momentum with strong moving averages, while fundamentals reveal rapid revenue growth to $502M in 2025 but persistent losses with a -144.4% net margin. Recent news highlights regulatory approvals for acoramidis and a $1B preferred equity raise to fund launches, driving positive sentiment despite earnings misses.
Outlook remains speculative with high execution risk; analyst consensus is strongly bullish (92% buy) targeting $104.57, but profitability challenges and heavy cash burn require successful pipeline commercialization to justify valuation. Key near-term catalysts include FDA decisions on BBP-418 and encaleret in 2026.
Fortinet (FTNT) trades at $160.62, up 1.97% on the day, with strong technical momentum and bullish moving averages. The company reported robust earnings beats in recent quarters, with Q1 2026 EPS of $0.82 exceeding the $0.619 estimate. Revenue growth remains solid, reaching $6.80B in 2025, while high valuation ratios like a P/E of 62.26 reflect premium investor expectations. Recent news highlights expansion in AI-driven security solutions, positioning FTNT to capitalize on rising cybersecurity demand.
The outlook for FTNT is positive, driven by sustained demand for cybersecurity and AI integration, though elevated valuations and competitive pressures pose risks. Analyst consensus is mixed with 42.65% buy ratings, but the average price target of $121.11 suggests caution relative to the current price. Investors should monitor execution against raised 2026 guidance and industry spending trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About Fortinet Inc
Fortinet is a cybersecurity vendor that sells products, support, and services to small and midsize businesses, enterprises, and government entities. Its products include unified threat management appliances, firewalls, network security, and its security platform, Security Fabric. Services revenue is primarily from FortiGuard security subscriptions and FortiCare technical support. At the end of 2021, products were 38% of revenue and services were 62% of sales. The California-based company sells products worldwide.
Read more on FTNT →
